4586 Stock Overview
A pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
MedRx Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥82.00 |
| 52 Week High | JP¥199.00 |
| 52 Week Low | JP¥76.00 |
| Beta | 1.16 |
| 1 Month Change | -10.87% |
| 3 Month Change | -14.58% |
| 1 Year Change | -45.70% |
| 3 Year Change | -35.43% |
| 5 Year Change | -72.58% |
| Change since IPO | -96.43% |
Recent News & Updates
Here's Why We're Not At All Concerned With MedRx's (TSE:4586) Cash Burn Situation
Sep 04
Companies Like MedRx (TSE:4586) Are In A Position To Invest In Growth
May 13Shareholder Returns
| 4586 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | 5.1% | 0.6% | 2.1% |
| 1Y | -45.7% | 11.8% | 15.6% |
Return vs Industry: 4586 underperformed the JP Pharmaceuticals industry which returned 11.8% over the past year.
Return vs Market: 4586 underperformed the JP Market which returned 15.6% over the past year.
Price Volatility
| 4586 volatility | |
|---|---|
| 4586 Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in JP Market | 7.2% |
| 10% least volatile stocks in JP Market | 1.8% |
Stable Share Price: 4586's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4586's weekly volatility has decreased from 11% to 5% over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 22 | Yonehiro Matsumura | www.medrx.co.jp |
MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops medicines based on Ionic liquid transdermal system (ILTS) and Nano-sized Colloid Transdermal System (NCTS); and researches and develops painless transdermal administration system for vaccines, nucleic acid medicines, protein medicines, etc. Its products pipeline includes MRX-4TZT, which is in phase I clinical trials for the treatment of spastic paralysis; MRX-9FLT that is in phase I clinical trials to treat chronic, cancer, and severe pain; and MRX-7MLL and MRX-6LDT that is in pre-clinical trials to treat Alzheimer’s disease and chronic pain, as well as MRX-5LBT that has completed the clinical trials for the treatment of postherpetic nerve pain. MedRx Co., Ltd was incorporated in 2002 and is headquartered in Higashikagawa, Japan.
MedRx Co., Ltd Fundamentals Summary
| 4586 fundamental statistics | |
|---|---|
| Market cap | JP¥3.88b |
| Earnings (TTM) | -JP¥581.00m |
| Revenue (TTM) | JP¥255.00m |
15.2x
P/S Ratio-6.7x
P/E RatioIs 4586 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4586 income statement (TTM) | |
|---|---|
| Revenue | JP¥255.00m |
| Cost of Revenue | JP¥1.00m |
| Gross Profit | JP¥254.00m |
| Other Expenses | JP¥835.00m |
| Earnings | -JP¥581.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -12.27 |
| Gross Margin | 99.61% |
| Net Profit Margin | -227.84% |
| Debt/Equity Ratio | 0% |
How did 4586 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 17:33 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
MedRx Co., Ltd is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kiyokazu Yamazaki | Ichiyoshi Research Institute Inc. |
| Dion Stéfan Büchner | Pathology Associates Co., Ltd. |